Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trialPaolo F. Caimi, Carmelo Carlo‐Stella, Yajuan Qin et al.|The Lancet Oncology|2021Cited by 428
Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell LymphomaPaolo F. Caimi, Carmelo Carlo‐Stella, Weiyun Z. Ai et al.|Blood|2020Cited by 17
LOTIS 2 FOLLOW‐UP ANALYSIS: UPDATED RESULTS FROM A PHASE 2 STUDY OF LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMAPier Luigi Zinzani, M. Hamadani, Paolo F. Caimi et al.|Hematological Oncology|2021Cited by 8
Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.Paolo F. Caimi, Carmelo Carlo‐Stella, Weiyun Z. Ai et al.|Journal of Clinical Oncology|2021Cited by 5
ABCL-022: LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell LymphomaBrad S. Kahl, Pier Luigi Zinzani, Mehdi Hamadani et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 3